

CERTIFICATE OF EXPRESS MAIL

I hereby certify that the foregoing Information Disclosure Statement and the accompanying Form PTO-1449 (1 sheet), a copy of the International Search Report, a copy of the International Preliminary Examination Report, a copy of the Written Opinion, a copy of the response to the Written Opinion, and copies of three (3) references are being deposited with the United States Postal Service as Express Mail under Label No. EV 586235786 US in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Date: 05 April 2005 By: Kimberly Brittingham

Attorney Docket No.: 102792-438 (10762P3)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT	:	Tak Wai CHEUNG et al
SERIAL NO.	:	To Be Assigned
CUSTOMER NO.	:	27389
FILED	:	05 April 2005
FOR	:	DISINFECTANT CLEANING COMPOSITIONS
ART UNIT	:	To Be Assigned
EXAMINER	:	To Be Assigned

05 April 2005

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicant(s) respectfully request that the Examiner consider the references listed on the attached Form PTO-1449.

I. Timeliness, Fees and Certifications in lieu of Fees

This Information Disclosure Statement is being filed within three months of the filing date of the application, or within three months of entry into the national stage, or before the mailing of a first Office Action on the merits. Pursuant to 37 CFR § 1.97(b),

consideration of this Information Disclosure Statement does not require a fee or a statement under 37 CFR § 1.97(e). However, should the Commissioner determine that a fee is, in fact, due, the Commissioner is hereby authorized to charge the fee to Deposit Account No. 14-1263.

II. Copies of Listed References

Copies of all references listed on the attached Form PTO-1449 are being supplied. Copies of U.S. patents are not included pursuant to Pre-OG Notice dated July 11, 2003.

III. Concise Statement of Relevance


All references listed on the attached Form PTO-1449 are in the English language, and, therefore, a concise statement of relevance is not required.

Consideration of the foregoing in relation to this application is respectfully requested.

Respectfully submitted,

NORRIS McLAUGHLIN & MARCUS, P.A.

By



Andrew N. Parfomak
Reg. No. 32,431
Attorney for Applicant(s)
875 Third Avenue
18th Floor
New York, New York 10022
(212) 808-0700

**LIST OF PATENTS AND PUBLICATIONS
APPLICANT'S INFORMATION
DISCLOSURE STATEMENT**
(Form PTO-1449)

Attorney Docket: 102792-438
(10762P3)

Serial No. To Be Assigned
10/530433

Applicant: CHEUNG et al

Examiner: To Be Assigned

Filing Date: 05 April 2005

Group: To Be Assigned

U.S. PATENT DOCUMENTS

Examiner's Initial		Document Number	Date	Name	Class	Sub Class	Filing Date If appropriate
	AA	5,763,468 A	09 June 1998	Barranx et al	510	383	
	AB	4,589,994 A	20 May 1986	Moseman	252	107	
	AC						
	AD						
	AE						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation Yes No	
	AF	GB 2 304 115 A	12 Mar. 1997	Great Britain	C11D	3/48		
	AG	WO 97 06230 A	20 Feb. 1997	WIPO	C11D	1/65		
	AH	GB 1 236 594 A	23 June 1971	Great Britain	C11D	9/00		
	AI							
	AJ							
	AK							
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AQ	International Search Report dated 16 January 2004 for Application No. PCT/GB03/04422
	AR	International Preliminary Search Report dated 29 September 2004 for Application No. PCT/GB03/02244
	AS	Written Opinion dated 29 April 2004 for Application No. PCT/GB03/04422
	AT	Response dated 28 July 2004 to Written Opinion for Application No. PCT/GB03/04422

EXAMINER:

DATE CONSIDERED:

- **EXAMINER:** Initial if Reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered, include copy of this form with next communication to applicant.